JNJ-26076713

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameJNJ-26076713
Drug Alias NameJNJ-26076713
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V antagonists
TargetsIntegrin alpha-V
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A